- Hemostemix (HEM) says in an interview with the second stem cell recipient reports one week with no chest pain
- Thomas Smeenk, CEO of Hemostemix, commented on how the study results and capitalization of the company compare
- One study says all patients tolerated cardiac rehabilitation very well. The 6-minute walk tests showed an improvement of nearly 36 per cent
- Hemostemix Inc. is a publicly-traded autologous stem cell therapy company.
- Hemostemix (HEM) is up 2.56 per cent, and is trading at C$0.20 as of 4 p.m. ET.
Hemostemix (HEM) reports positive results from an interview with the second stem cell recipient.
In its second series of video interviews with stem cell recipients, patient Peter recounts how his chest pain dissipated one week after his stem cell treatment and how he felt like his life was back to normal after only six weeks.
Thomas Smeenk, CEO of Hemostemix, commented on how the study results and capitalization of the company compare.
“It is interesting to listen to Peter following his treatment, compare the study results published about ACP (angiogenic cell precursors) and Mavacamten with respect to dilated cardiomyopathy, and then compare the market capitalization of Hemostemix [$11.5 Million] to the $13.1 Billion takeover of Myokardia by Bristol Myers Squibb because both therapeutics resulted in an improvement in ejection fraction, both therapeutics resulted in a significant improvement in NYHA [New York Heart Association] functional class and the ACP group measured a 36 per cent improvement in walking capacity in 6 minutes,” says Smeenk.
A co-founder of the Minnesota Heart Institute, Dr. Kit Arom, published his findings of the efficacy of a direct injection of ACP in patients with end-stage dilated cardiomyopathy.
It stated that 41 patients in their 50’s with cardiomyopathy underwent ACP stem cell injection, including 21 with dilated cardiomyopathy and 20 with ischemic cardiomyopathy. All patients tolerated cardiac rehabilitation very well. The 6-minute walk tests showed an improvement of nearly 36 per cent.
On October 21, 2019, Hemostemix announced the results from its phase two trial presentation entitled “Autologous Stem Cell Treatment for CLI Patients with No Revascularization Options: An Update of the Hemostemix ACP-01 Trial With 4.5 Year Follow-up,” which noted healing of ulcers and resolution of ischemic rest pain occurred in 83 per cent of patients, with outcomes maintained for up to four and a half years.
Hemostemix Inc. is an autologous stem cell therapy company commercializing ACP-01 for the treatment of CLI, PAD, angina, ischemic cardiomyopathy, dilated cardiomyopathy and other conditions of ischemia.
Hemostemix owns 91 patents across five patent families titled: Regulating Stem Cells, In Vitro Techniques for use with Stem Cells, Production from Blood of Cells of Neural Lineage, and Automated Cell Therapy.
Hemostemix (HEM) is up 2.56 per cent, and is trading at C$0.20 as of 4 p.m. ET.
